论文部分内容阅读
目的:评估比索洛尔对肺源性心脏病(肺心病)心力衰竭的疗效。方法:将肺心病心力衰竭患者40例随机分为两组,常规治疗组18例和比索洛尔组22例。常规治疗组予以抗感染、吸氧、解痉平喘、止咳化痰、纠正水电解质及酸碱平衡等治疗;比索洛尔组在常规治疗的基础上,加比索洛尔1.25~5mg/d,口服2~4周为1疗程,治疗中严密监测各项相关指标。结果:治疗2~4周后,比索洛尔组总有效率为72.27%,常规治疗组为61.11%,两组比较有显著性差异(P<0.05)。结论:加用比索洛尔治疗肺心病心力衰竭其疗效优于常规治疗组,且未发现明显的副作用。
PURPOSE: To evaluate the efficacy of bisoprolol in heart failure with pulmonary heart disease (pulmonary heart disease). Methods: 40 cases of heart failure patients with cor pulmonale were randomly divided into two groups, 18 cases in conventional treatment group and 22 cases in bisoprolol group. The conventional treatment group was given anti-infective, oxygen inhalation, antispasmodic and antiasthmatic, relieving cough and phlegm, correcting water and electrolyte and acid-base balance and other treatments. On the basis of conventional treatment, bisoprolol group received 1.25 ~ 5 mg / ~ 4 weeks for a course of treatment, the treatment of closely monitoring the relevant indicators. Results: After 2 to 4 weeks of treatment, the total effective rate was 72.27% in the bisoprolol group and 61.11% in the conventional treatment group, with significant difference between the two groups (P <0.05). Conclusion: Bisoprolol in the treatment of heart failure with cor pulmonale is superior to the conventional treatment group, and no obvious side effects are found.